术前替雷利珠单抗联合低剂量白蛋白结合型紫杉醇治疗肌层浸润性膀胱癌的2期研究
TRUCE-01是一项单臂2期研究,纳入62例T2-4a N0/X M0肌层浸润性膀胱癌患者,接受3个21天周期的替雷利珠单抗200 mg联合低剂量白蛋白结合型紫杉醇200 mg术前治疗。安全性分析62例中6例(9.7%)发生≥3级治疗相关不良事件;疗效分析48例中25例(52%)达到临床完全缓解。结论认为该方案抗肿瘤疗效有前景且总体耐受良好。
要点
- 62例肌层浸润性膀胱癌患者接受替雷利珠单抗联合低剂量白蛋白结合型紫杉醇术前治疗。
- 疗效分析48例中25例(52%)达到临床完全缓解。
- 安全性分析62例中6例(9.7%)发生≥3级治疗相关不良事件。
核心结论
- 替雷利珠单抗联合低剂量白蛋白结合型紫杉醇显示出有前景的抗肿瘤疗效且总体耐受良好,是肌层浸润性膀胱癌优秀的术前治疗选择。
研究设计与样本
- TRUCE-01为单臂2期研究,纳入62例T2-4a N0/X M0、以尿路上皮癌组织学为主的肌层浸润性膀胱癌患者。
- eligible患者接受3个21天周期静脉替雷利珠单抗200 mg(第1天)联合静脉白蛋白结合型紫杉醇200 mg(第2天),随后进行手术评估。
- 主要研究终点为临床完全缓解(cCR),治疗相关不良事件(TRAE)按不良事件通用术语标准5.0版记录。
主要发现
- 安全性分析纳入全部62例患者,疗效分析纳入48例患者。
- 疗效分析48例中25例(52%)达到主要疗效终点cCR。
- 安全性分析62例中6例(9.7%)发生≥3级TRAE。
临床怎么用
- 作者认为替雷利珠单抗联合低剂量白蛋白结合型紫杉醇是肌层浸润性膀胱癌优秀的术前治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Combinations of immune checkpoint inhibitors and nab-paclitaxel have achieved significant therapeutic effects in the treatment of advanced urothelial carcinoma. Our aim was to assess the efficacy and safety of tislelizumab combined with low-dose nab-paclitaxel in patients with muscle-invasive bladder cancer (MIBC). METHODS: TRUCE-01 was a single-arm phase 2 study that included 62 patients with T2-4a N0/X M0 MIBC tumors with predominant urothelial carcinoma histology. Eligible patients received three 21-d cycles of intravenous 200 mg tislelizumab on day 1 plus intravenous 200 mg nab-paclitaxel on day 2, followed by surgical assessment. The primary study endpoint was a clinical complete response (cCR). Treatment-related adverse event (TRAE) profiles were recorded according to Common Terminology Criteria for Adverse Events version 5.0. KEY FINDINGS AND LIMITATIONS: The safety analysis included all 62 patients and the efficacy analysis included 48 patients. The primary efficacy endpoint (cCR) was met by 25 patients (52%) patients. Among the 62 patients in the safety analysis, six (9.7%) had grade ≥3 TRAEs. CONCLUSIONS: Tislelizumab combined with low-dose nab-paclitaxel showed promising antitumor effectiveness and was generally well tolerated, which makes it an excellent preoperative therapy option for MIBC. PATIENT SUMMARY: We found that a combination of the drugs tislelizumab and low-dose nab-paclitaxel had satisfactory efficacy and safety for preoperative treatment of muscle-invasive bladder cancer.
引用
- Wu Z, Zhao G, Zhang Z, et al. Phase 2 Study of Preoperative Tislelizumab in Combination with Low-dose Nab-Paclitaxel in Patients with Muscle-invasive Bladder Cancer. Eur Urol Oncol. 2024. PMID: 38762368. doi:10.1016/j.euo.2024.04.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。